New England Journal of Medicine· 2022Q1
Tirzepatide Once Weekly for the Treatment of Obesity
- 3,298citations
- Q1SCImago
- 2022year
Short summary
Once-weekly tirzepatide (5, 10, or 15 mg) resulted in substantial body weight reduction in adults with obesity, with the 15-mg dose achieving a mean 20.9% decrease over 72 weeks.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine